亞馬遜推出人工智慧平台，加速藥物研發進程
Amazon Launches AI Platform to Speed Up Drug Discovery
亞馬遜近期發表了「亞馬遜生物發現」（Amazon Bio Discovery），這是一個由人工智慧驅動的平台，旨在加速早期藥物開發。
Amazon recently unveiled Amazon Bio Discovery, an AI-powered platform designed to accelerate early-stage drug development.
該平台提供「無代碼」介面，讓實驗室科學家無需具備廣泛的程式編寫技能，即可進行複雜的運算研究。
By offering a "no-code" interface, the platform allows lab scientists to perform complex computational research without needing extensive programming skills.
該工具的核心在於利用生物學基礎模型與AI代理程式，協助研究人員篩選潛在的藥物分子。
At its core, the tool utilizes biological foundation models and AI agents to help researchers identify potential drug molecules.
這項技術能顯著縮短篩選候選藥物的時間，從18個月縮短至僅需幾週。
This technology can dramatically reduce the time required to shortlist candidates from 18 months to just a few weeks.
該平台並非為了取代人類專業知識，而是為了賦能科學家，以解決全球運算生物學家短缺的問題。
Rather than replacing human expertise, the platform aims to empower scientists, addressing the global shortage of computational biologists.
透過大眾化高階AI研究工具的使用，亞馬遜正將自身置於製藥創新的最前沿。
By democratizing access to high-end AI research tools, Amazon is positioning itself at the forefront of pharmaceutical innovation.
該計畫已獲拜耳（Bayer）等業界巨頭採用，這代表著醫療研究方式的重大演進，有望降低藥物發現所伴隨的鉅額成本與長期時程。
Already adopted by industry giants like Bayer, this initiative represents a major evolution in how we approach healthcare research, potentially lowering the massive costs and long timelines associated with drug discovery.
